July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Basal Cell Carcinoma-Associated Retinopathy and Optic Neuropathy (BARN): A Novel Paraneoplastic Entity
Author Affiliations & Notes
  • Alessandro Iannaccone
    Duke Eye Center, Duke University Medical Center, Durham, North Carolina, United States
  • Faith Birnbaum
    Duke Eye Center, Duke University Medical Center, Durham, North Carolina, United States
  • Rachel Champaigne
    Casey Eye Institute, Ocular Immunology Lab, Oregon Health Sciences University, Portland, Oregon, United States
  • Grazyna Adamus
    Casey Eye Institute, Ocular Immunology Lab, Oregon Health Sciences University, Portland, Oregon, United States
  • Footnotes
    Commercial Relationships   Alessandro Iannaccone, None; Faith Birnbaum, None; Rachel Champaigne, None; Grazyna Adamus, None
  • Footnotes
    Support  Research to Prevent Blindness, Inc. New York, NY (Unrestricted grant to Duke Eye Center), Duke Retinal Degenerations Research Fund
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2780. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alessandro Iannaccone, Faith Birnbaum, Rachel Champaigne, Grazyna Adamus; Basal Cell Carcinoma-Associated Retinopathy and Optic Neuropathy (BARN): A Novel Paraneoplastic Entity. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2780. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report the ophthalmological and serological characteristics of the newly identified paraneoplastic visual loss syndrome in patients with recent history of basal cell carcinoma (BCC) and positive for autoantibodies (AAbs), recognizing retinal, retinal pigment epithelium (RPE) and/or optic nerve (ON) antigens.

Methods : Twenty-eight cases of BARN were identified (14F/14M, 48-87 yo). Serologies included immunoblotting for anti-retinal, anti-RPE AAbs , and anti-ON AAbs and retinal immunohistochemistry (IHC). A BCC tissue sample was available for IHC. We report summary data for all subjects and report on 8 subjects examined in detail with visual fields (VFs), full-field flash electroretinograms (ffERG), pattern visual evoked potentials (PVEPs) and various imaging methods.

Results : Multiple anti-retinal, anti-RPE (incuding anti-RPE65, which is found also in the human epidermis), and anti-ON AAbs were detected. Most cases had bilateral but variable and asymmetricvisual acuity and VF loss, and abnormal ffERGs. In the 8 subjects examined in detail, ffERG abnormalities varied from mild cone dysfunction to severe rod and cone compromise. RPE loss wasseen clinically and by fundus autofluorescence, ranging from punctate patterns to large atrophic RPE patches. All cases with PVEP abnormalities and delays(5/8), which were independent of acuity, had anti-ON AAbs, labeled retinal ganglion cell (RGC) and/or retinal nerve fiber layer (RNFL) on IHC, and typically exhibited RNFL changes on optical coherence tomography (OCT). The ellipsoid zone (EZ) was spared foveally in all cases, but there was often overt retinal degeneration peripherally and EZ loss in the perimacular region. In the case for which BCC tissue was available for IHC, there was marked staining of the cancer cells by the patient’s AAbs.

Conclusions : The BARN association had not been previously reported. Our study show a strong association with the observed AAbs, and especially the anti-RPE65 AAbs, strongly suggesting that BARN is a novel paraneoplastic entity triggered by an autoimmune reaction initiated by BCC antigens. Both retinal and optic nerve compromise, mostly intraretinally at the RGC/RNFL level, existed in numerous cases and the latter was often the main acuity loss determinant. History of BCC should be sought out in patients with suspected paraneoplastic vision loss.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×